668results about How to "Improve Medication Adherence" patented technology

An ingestible dosage form includes a pill containing a pharmaceutical content and an RF tag associated with the pill. The RF tag is configured to output a wireless response signal in response to a wireless excitation signal received by the RF tag from an RF reader. The ingestible dosage form includes memory for storing pill identifying information. The wireless response signal includes the pill identifying information which may be received and processed by the RF reader. A system for monitoring patient medicine intake compliance includes a monitoring device placed within communicative proximity of ingestible dosage forms to transmit the wireless excitation signal and receive the wireless response signal including pill identifying information from the ingestible dosage forms. A device for determining an identity of a pill and quantity thereof ingested by an individual includes a nasogastric / orogastric tube having an RF tag reader attached thereto for detecting RF tagged pills.

A highly safe and effective prophylactic / ameliorating or therapeutic agent for NACH and the method for using the same are provided.A prophylactic / ameliorating or therapeutic agent for NASH containing a combination of at least one first ingredient selected from the group consisting of an ω3PUFA and pharmaceutically acceptable salts and esters thereof and at least one second ingredient selected from the group consisting of (a) a biguanide hypoglycemic agent, (b) a nonsteroidal anti-inflammatory drug, (c) a 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitor, and (d) an angiotensin II receptor blocker as the active ingredients; and its method of use.

A self-emulsifying composition contains: 70 to 90% by weight of at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 0.5 to 6% by weight of water; 1 to 29% by weight of a polyoxyethylene sorbitan fatty acid ester as an emulsifier (optionally including a polyoxyl castor oil, and not including lecithin); and lecithin in an amount of 3 to 40 parts by weight in relation to 100 parts by weight of ω3 polyunsaturated fatty acids and the like. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.

The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.

A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

A pharmaceutical composition includes a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-S-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-S-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

The present invention relates to a composition for the prevention or treatment of diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a therapeutic method for the treatment of diabetes, and more particularly, concurrent administration of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain caused by insulin treatment, and vomiting and nausea caused by insulinotropic peptide treatment, and reduces the required dose of insulin, thereby remarkably improving drug compliance. Moreover, each of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate of the present invention is prepared by linking insulin or insulinotropic peptide with an immunoglobulin Fc region via a non-peptidyl linker, thereby showing improved in-vivo duration of efficacy and stability.

A oral disintegating tablet of gingko leaf for treating coronary heart disease, angina pectoris, acute cerebral infaction and cerebral arte riosclerosis is prepared from the extract of gingko leaf, filler, disintegrant, flavouring, flowing aid, lubricant, etc.

The present invention relates to a functional combination preparation comprising a dihydropyridine-based calcium channel blocker such as amlodipine and an ARB (Angiotensin-2 receptor blocker) such as losartan. In particular, the present invention relates to a chronotherapeutical combination pharmaceutical formulations with controlled-release for the prevention or treatment of cardiovascular disease, which is formulated in accordance with xenobiotics and chronotherapy for enabling the two drugs to be chronotherapeutically released, thereby improving the therapeutic activity as compared to the co-administration of each drug in the form of a single pill, while reducing side effects and maintaining the therapeutic activity as high as possible at the time of day when the risk of a complication of cardiovascular disease is highest.

The present invention relates to a pharmaceutical composition comprising benzyl alcohol and polyoxyethylene derivatives of sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.

The invention provides a long-acting microsphere injection as an antidiabetic medicament, the long-acting microsphere injection comprises liraglutide, PLGA (poly(lactic-co-glycolic acid)), excipients and a surfactant, and the invention simultaneously relates to a preparation method of the injection. Liraglutide long-acting sustained-release microspheres provided by the invention are designed to perform subcutaneous injection once every 28 days, thereby greatly reducing treatment burden on a patient, improving medication compliance and reducing treatment cost; simultaneously, results of in vitro release studies, animal experiments and the like prove that the obtained sustained-release microspheres can slowly release a medicament for a long time in vitro and in vivo.

The present invention relates to a pharmaceutical composition comprising glycerol esters of a fatty acid, wherein the compositions are useful for the delivery of anti-psychotic drugs.

The present invention relates to an injectable, pharmaceutical composition comprising a C1-6 alkyl ester of a C10-20 fatty acid. In an embodiment, the fatty acid is ethyl oleate, isopropyl oleate, ethyl myristate, or isopropyl myristate. These compositions are useful for the delivery of anti-psychotic drugs.

The invention relates to a method for improving medication compliance of a patient and an intelligent medicine box system. The method comprises the following steps: arranging the intelligent medicine box system which comprises an intelligent medicine box device, a cloud platform and a mobile phone APP, wherein the intelligent medicine box device comprises a central processing module, a real-time clock module, a camera module, a wireless communication module, an MP3 play module, a sensor module, a memory module and a loudspeaker; establishing a knowledge base, and arranging contents of the knowledge base at different time points of the course of treatment to form a stepped health education knowledge base; recording knowledge contents of the knowledge base into a voice file, then translating the file into different language versions, and performing classified hierarchical storage; copying the voice file together with a catalogue to a memory card of the intelligent medicine box device; calculating the medication time when the patient takes medicine every time, retrieving the voice file with the same name of times or days in the corresponding catalogue in the knowledge base on the memory card, and finally achieving the synchronous health education in the process of medication of the patient in a way of playing or prompting the patient to listen.

The invention belongs to the field of medical biology, and particularly relates to a method for extracting a konjac polypeptide extract from konjac flying powder, the konjac polypeptide extract obtained by the method and an application of the konjac polypeptide extract. In order to increase the content of konjac polypeptide in the konjac polypeptide extract, the optimized extraction technology provided by the invention adopts a complex enzyme to perform enzymolysis on the protein extraction liquid of the konjac flying powder; in the finally obtained konjac polypeptide extract, the content of konjac polypeptide is as high as 85-97%, and the molecular weight of the konjac polypeptide is 350-3500Da. Moreover, the invention also provides an application of the konjac polypeptide extract in preparing a medicine for treating diabetes and diabetic complications as well as a hypoglycemic medicinal composition containing the konjac polypeptide extract. In a word, the konjac polypeptide extract and the medicinal composition thereof provided by the invention have good prospect in medicine.

Belonging to the technical field of disinfection, the invention discloses a skin disinfection gel to solve the disadvantages of existing disinfection technologies, especially preoperative disinfection technologies. The skin disinfection gel is composed of the following active components by mass: 1.5%-6% of chitosan, 1.5-10% of chitosan oligosaccharide, 2%-8% of baicalin, 0.5%-2% of chlorhexidine, 0.5%-1.5% of sodium alginate, 2%-5% of agarose, and 1.5%-5% of a mint extract. And the disinfection effect is good. The disinfection gel disclosed in the invention can be used for hand disinfection or skin disinfection in sanitary disinfection or preoperative disinfection, and with excellent disinfection effects and lasting function, it has very good application prospects and economic benefits.

The invention relates to an external composition, and a preparation and an application thereof and belongs to the field of medicines. The external composition provided by the invention is a medicine composition which contains chlorhexidine or officinal salt thereof, or benzalkonium bromide or officinal salt thereof and a recombinant human epidermal growth factor or a recombinant cattle alkali fibroblast growth factor. According to the invention, the medicine composition is also further prepared into gel, liniment, ointment or paste, and the gel further comprises chitosan or officinal salt thereof and hyaluronic acid or officinal salt thereof. When being used for treating vagina inflammation, the external composition disclosed by the invention can improve a vagina microenvironment, promote growth of granulation tissue and repair vagina micro damage; and when being used for skin wound atraumatic restorative treatment, the external composition also can speed up restoration and regeneration of a wound tissue, promote healing and reduce scar formation, so that the external composition has a wide medical application prospect.

The invention relates to an oral preparation containing andrographolide and a preparation method thereof, belonging to the field of medicines. The oral preparation containing andrographolide is in dosage forms of enteric-coated granules, enteric-coated tablets, enteric-coated capsules and enteric-coated dispersible tablets which are prepared by mixing andrographolide and pharmaceutically acceptable auxiliary materials. The prepared oral preparation can reduce incidence of adverse reactions and side effects thereof and improve the medication safety while ensuring the therapeutic effect, and uses the andrographolide more widely.

The invention relates to the technical field of devices and methods for supervising the medicine taking of patients, and discloses a device for supervising the medication compliance of a patient and tracking medication effects and a using method of the device. The device for supervising the medication compliance of the patient and tracking the medication effects comprises a medicine box, an intelligent terminal device, a patient mobile phone and a cloud service platform, wherein the intelligent terminal device is fixedly arranged in the medicine box, and comprises a shell; a sensor capable of sensing the opening of the medicine box, a wireless communication module, a timed reminding module, a sensing module and a power module are arranged in the shell. According to the device for supervising the medication compliance of the patient and tracking the medication effects and the using method of the device, the patient can effectively execute a medication plan, and can be effectively supervised to take medicine, the medication effects of the patient can be effectively tracked, the medication compliance of the patient is improved, and an important basis is provided for the subsequent treatment of the patient.

The present invention provides a pharmaceutical composition for nasal administration comprising mometasone furoate and azelastine hydrochloride, wherein the pharmaceutical composition comprises thaumatin as an agent for reducing bitterness and irritation.

A system, method and platform are herein provided for enabling social medication adherence enhancement. According to one embodiment a system or platform is provided for socially supporting medication adherence management, comprising a user application for managing medication adherence; a data server with memory thereon for storing medication adherence related data; a web server running code to enable social medication adherence tracking, by sharing user application data with a selected social group; and one or more of sensors for tracking medication adherence related stimuli and cross-checking medication data with data generated from sensors to inform users.

The invention belongs to the technical field of medicines, and in particular relates to a traditional Chinese medicinal composition for treating solar dermatitis and a preparation method thereof. To overcome the defects of large hepatotoxicity and poor curative effect of a current chemical treatment medicament for treating solar dermatitis in the prior art, the traditional Chinese medicinal composition for treating or preventing solar dermatitis comprises the following components in parts by weight: 10-50 parts of purslane, 10-20 parts of notopterygium root, 5-20 parts of sophora flower, 5-15 parts of scutellaria baicalensis, 5-10 parts of prepared rehmannia root, 5-15 parts of lily, 5-15 parts of honeysuckle, 1-10 parts of dandelion, 5-15 parts of medlar, 9-15 parts of sculellaria barbata, 9-15 parts of ligusticum wallichii, 5-15 parts of angelica root, 0.2-9 parts of berberine, 5.5-15 parts of radix paeoniae alba, 6-9 parts of dried ginger and 10-15 parts of liquorice. The traditional Chinese medicinal composition has a good effect in preventing or treating solar dermatitis, has low toxic and side effects, and has a remarkable clinical popularization value.